AVITA Medical Gets FDA Approval on Vitiligo Treatment
By Ben Glickman
AVITA Medical said it had received premarket approval from the U.S. Food and Drug Administration for its treatment of vitiligo.
The company's RECELL System allows for repigmentation of skin lesions for patients with vitiligo, a disease which causes loss of pigment in areas of the skin.
The Valencia, Calif.-based medical company said its treatment was the first FDA-approved therapeutic device for single treatment of vitiligo, which affects up to 2% of the world's population.
Premarket approval by the FDA was based on the results of a trial evaluating the RECELL System for use in patients with vitiligo. The treatment technology has also previously been approved for treatment of burns and skin defects by the FDA.
Shares rose 0.47%, to $17.03, in late afternoon trading.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
June 16, 2023 15:38 ET (19:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?